In a recent “Ask the Author” session, Professor Kudo discussed the LEAP-012 trial and its implications for treating hepatocellular carcinoma (HCC) with Professor Dufour. The study, titled “TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic HCC LEAP-012,” investigates a novel approach to treating this condition. Watch the Full Interview here Background
Category: Uncategorised
HCC 2024 Event registration
The HCC event in 2024 will be happening on the 29th of February. The program and registration can be found here